Apricus Biosciences Inc (APRI) : 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Apricus Biosciences Inc (APRI). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 2 Wall Street Analysts endorse the stock as a Buy with a rating of 2.5.
Apricus Biosciences Inc (APRI) : The highest level Apricus Biosciences Inc (APRI) is projected to reach is $1 for the short term and the lowest estimate is at $1. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $0.88 and the possibility the share price can swing is $0.53.
Apricus Biosciences Inc (NASDAQ:APRI): After opening at $0.4, the stock dipped to an intraday low of $0.3805 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $0.494 and the buying power remained strong till the end. The stock closed at $0.4373 for the day, a gain of 12.13% for the day session. The total traded volume was 5,451,734. The stocks close on the previous trading day was $0.39.
Apricus Biosciences, Inc. is a pharmaceutical company focused on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology. The Companys drug delivery technology is a permeation enhancer called NexACT. The Company has one approved drug, Vitaros, which uses the NexACT delivery system, and is approved for the treatment of erectile dysfunction (ED) in Canada and through the European Decentralized Procedure (DCP) in Europe. The Companys other pipeline includes RayVa, Fispemifene and Femprox. RayVa utilizes the Companys permeation enhancer for the treatment of Raynauds phenomenon secondary to scleroderma. Fispemifene a tissue-specific selective estrogen receptor modulator (SERM) used for the treatment of secondary hypogonadism. Femprox is used for the treatment of female sexual interest and arousal disorder (FSIAD). The Company owns or exclusively licenses approximately 331 issued patents and 194 patent applications.